Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

The Oncologist(2023)10.1093/oncolo/oyad317Source: DataRank Database

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma is a research paper published in The Oncologist (2023). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.32)OA: goldTopics (36)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Wei Qaio,Yu Shen ORCID,Akshara Singareeka Raghavendra ORCID,Debasish Tripathy,Rachel M. Layman ORCID

Live enrichment

PubMed:38070191 PMC:PMC10911914 OpenAlex:https://openalex.org/W4389503993

Cancer Prevention and Research Institute of Texas

Grant: MIRA RP170067

Cancer Prevention and Research Institute of Texas

Grant: RP170079

Cancer Prevention and Research Institute of Texas

Grant: RP180712

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

NIH

NCI

FWCI

0.32

Citation Percentile

0.5%

Citation Trend

2024

2025

goldLicense: cc-by

journalhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad317/54192924/oyad317.pdf

publisherhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad317/54192924/oyad317.pdf

publisherhttps://academic.oup.com/oncolo/article-pdf/29/3/213/56831452/oyad317.pdf

journalhttps://doi.org/10.1093/oncolo/oyad317

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38070191

Fields of Study

Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesCancer Treatment and Pharmacology03 medical and health sciences0302 clinical medicine

MeSH Terms

CapecitabineAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansProspective StudiesCarcinoma, LobularReceptor, ErbB-2Erb-b2 Receptor Tyrosine Kinases

Keywords

CapecitabineMedicineInternal medicineMetastatic breast cancerOncologyRefractory (planetary science)ChemotherapyBreast cancerCancerGastroenterologyBiologyTaxaneInvasive Lobular CarcinomaIlcHormone Receptor PositiveCarcinoma, LobularAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleBreast NeoplasmsProspective StudiesErb-b2 Receptor Tyrosine Kinases

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being